

2-5 March, 2017
Cannes, France



FIXED COMBINATION

The 7th International Conference on Fixed Combination Therapy in Cardiovascular Disease, Hypertension, Diabetes, Dyslipidemia and the Cardio-Metabolic Syndrome



Final Program as at 19 February, 2017

Thursday, 2 March, 2017

16:00-18:00 Registration

18:00-19:00 Get-Together Reception

Friday, 3 March, 2017

07:30 Registration

09:00-09:15 Opening Ceremony:

Hall A

Greetings by:
Prof. Talma Rosenthal, Israel, Honorary Chair
Prof. Giuseppe Mancia, Italy, Honorary Chair
Prof. Reuven Zimlichman, Israel, Chair

09:15-10:30 Plenary Session 1: Fixed Combination and Cardiovascular Disease

Hall A

Chairs: **Talma Rosenthal**, Israel; **Alberto Zanchetti**, Italy

09:15 Long Term Advantages of Initial Combination Treatment: New Evidence
Giuseppe Mancia, Emeritus Professor of Medicine, University Milano-Bicocca, Milano, Italy

09:40 Combination Therapy in the Cardiometabolic Syndrome
Reuven Zimlichman, Sackler Faculty of Medicine, Tel Aviv University, The E. Wolfson Medical Center, Holon, Israel

10:05 Can a Polypill, One Single Tablet, Combat Different Cardiovascular Risk Factors?
Talma Rosenthal, Sackler Faculty of Medicine, Tel Aviv University, Israel

10:30-11:00 Coffee Break, Exhibition Visit and Posters Viewing

11:00-12:20 Plenary Session 2: Hypertension and Combination Therapy

Hall A

Chairs: **Giuseppe Mancia**, Italy; **Reuven Zimlichman**, Israel

11:00 Benefits and Burdens of Antihypertensive Treatment: Meta-Analyses of Randomized Controlled Trials
Alberto Zanchetti, Emeritus Professor of Internal Medicine at the University of Milan, Italy

11:25 Inhibition of SGLT-2 and Antihypertensive Treatment Strategies: New Mechanisms of Cardiovascular Protection
Jan Menne, Dept. of Nephrology and Hypertension Medicine, University of Hannover, Hannover Medical School, Germany

11:50 Vascular Biology of Hypertension: Clinical Implications
Rhian M. Touyz, Institute of Cardiovascular Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK

12:15 Discussion

12:30-13:30 Lunch Break, Exhibition Visit and Posters Viewing

13:30-15:30 Plenary Session 3: Hypertension and Metabolic Syndrome **Hall A**
Chairs: **Rhian M. Touyz**, UK; **Jan Menne**, Germany

13:30 Arterial Destiffening in Hypertensive Patients with Type 2 Diabetes
Stephane Laurent, Dept. of Clinical Pharmacology in the Hôpital Européen Georges Pompidou, France

13:55 Metabolic Syndrome: Does it Exist?
Dimitri Mikhailidis, University College London, UK

14:20 Target BP in the Elderly and use of Combination Treatment
Enrico Agabiti-Rosei, Dept. of Clinical and Experimental Sciences, University of Brescia, Brescia Medical School, Italy

14:45 From Epidemiological Transition to Modern Cardiovascular Epidemiology: Hypertension in the 21st Century
Jacques Blacher, Hypertension and cardiovascular prevention unit, Hôtel-Dieu university Hospital, Assistance Publique-Hôpitaux de Paris, University Paris Descartes, Paris, France

15:10 Correct Combinations of Antihypertensive Drugs According to the Principles of Clinical Pharmacology
Stefano Taddei, Dept. of Clinical and Experimental Medicine, University of Pisa, Italy

15:30-16:00 Coffee Break, Exhibition Visit and Posters Viewing

16:00-17:00 Plenary Session 4: The Kidney and Vascular Disease **Hall A**
Chairs: **Jean-Michel Halimi**, France; **Dimitri Mikhailidis**, UK

16:00 Combination Antihypertensive Therapy in Chronic Kidney Disease: Does SPRINT tell us the Truth?
Alexander Kirsch, Medical University Graz, Department of Internal Medicine, Clinical Division of Nephrology, Graz, Austria

16:20 Which Combination Therapy in the Renal Patient?
Jean-Michel Halimi, Service de Néphrologie, CHU Tours, France

16:40 Total Cardiovascular Risk Evaluation and Management in patients with PAD
Marianne Brodmann, Dept. of Internal Medicine, Medical University Graz, Austria

Saturday, 4 March, 2016

07:30 Registration

08:45-10:00 Plenary 5: Heart Failure and Hemodynamics **Hall A**
Chairs: **Damiano Rizzoni**, Italy; **Jean-Michel Halimi**, France

08:45 Need for Pleiotropic Therapy in Chronic Heart Failure
Dirk L. Brutsaert, Professor-Emeritus, University of Antwerp, Antwerp, Belgium

09:10 Optimal Treatment of Heart Failure: Is there a Place of Combination Therapy?
Amitai Elkayam, Assuta Medical Center, Tel Aviv, Israel

09:35 Cross-Talk between Microcirculation and Macrocirculation: Effects of Combination Treatment
Damiano Rizzoni, Dept. of Medical and Surgical Sciences, University of Brescia, Italy

10:00-10:30 Coffee Break, Exhibition Visit and Posters Viewing

10:30-11:10 Plenary Session 6: Lipids and Combination Therapy **Hall A**
Chairs: **Dirk L. Brutsaert**, Belgium, **Amitai Elkayam**, Israel

10:30 PCSK9: Together or Alone? Current State of Knowledge 2017
Maciej Banach, Dept. of Hypertension, Medical University of Lodz, Poland

10:50 Advance towards Personalized Treatment for Prevention of Atherosclerotic Cardiovascular Disease: Genetics Proteomics Immunology and Optimal Choice of Treatment, the Future is here
Dov Gavish, Medicine A Wolfson, Sackler Faculty of Medicine Tel Aviv University, Israel

11:10-12:25 Plenary Session 7: Free Communications **Hall A**
Chairs: **Damiano Rizzoni**, Italy; **Reuven Zimlichman**, Israel

- 11:10 Use of Polypill Components among a Swiss Population-Based Study
Julien Castioni, Dept. of Medicine, Internal Medicine, Lausanne University Hospital, Switzerland
- 11:25 Fixed Dose Combination Olmesartan/Amlodipine Decreases Blood Pressure and Improves Ventricular-Arterial Coupling
Iana Simova, Dept. of Cardiology, Acibadem City Clinic - University Hospital, Bulgaria
- 11:40 Antihypertensive Efficacy and Uric Acid Lowering Effect of the Combination of Losartan Hydrochlorothiazide and Amlodipine Compared with a Combination of Bisoprolol Hydrochlorothiazide and Amlodipine
Olena Torbas, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D.Strazhesko, Ukraine
- 11:55 A Cross Sectional Study of Metformin Induced Vitamin B12 Deficiency in Metabolic Syndrome Patients among North Indian Rural Population
Hariharan Munganda, Internal Medicine and Endocrinology, Asian Institute of Medical Sciences, India
- 12:10 Rosuvastatin/Olmesartan FDC for the Treatment of CAD
Vuong Trieu, Clinical Research, Stocosis, USA

12:30-13:30 Lunch Break, Exhibition Visit and Posters Viewing

13:30-15:30 Plenary Session 8: Diabetes and Combination Therapy **Hall A**
Chairs: **Maciej Banach**, Poland; **Bernard I. Levy**, France

- 13:30 Outcomes of iGlarLixi, a Titratable Fixed-ratio Combination of Insulin Glargine/Lixisenatide, versus Insulin Glargine and Lixisenatide by Baseline Characteristics: LixiLan-O Trial
Bruno Guerci, University of Lorraine and Brabois Adult Hospital, Vandœuvre-lès-Nancy, France
- 13:50 Fixed Dose Combinations with Empagliflozin
Eberhard Standl, Munich Diabetes Research Group e.V. at Helmholtz Centre, Munich, Germany
- 14:10 Arguments for Early Fixed-Dose Glucose Lowering Combination Therapies
Guntram Schernthaner, Dept. of Medicine I, Rudolfstiftung Hospital, Vienna, Austria
- 14:30 Why and How do We Have to Use Drugs Combinations for Treatment of Hypertensive Patients
Bernard I. Levy, Emeritus Professor of Physiology, France
- 14:50 New Opportunities from GLP-1 RA Combination Therapies in Type 2 Diabetes
Francesco Giorgino, University of Bari Aldo Moro, Bari, Italy
- 15:10 Discussion

15:30-16:00 Coffee Break, Exhibition Visit and Posters Viewing

16:00-16:50 Plenary Session 9: Therapy and Hypertension Therapy **Hall A**
Chairs: **Guntram Schernthaner**, Austria; **Dov Gavish**, Israel

- 16:00 Novel Combination Therapy in Hypertension: Chlorthalidone with Spironolactone
Uday Jadhav, Dept. of Cardiology, MGM New Bombay Hospital, Vashi, India
- 16:25 HOPE-3: Efficacy and Safety of Combined BP and Lipid Lowering for Primary Prevention of Cardiovascular Disease
Basil S. Lewis, Lady Davis Carmel Medical Center, The Ruth and Bruce Rappaport School of Medicine of the Technion, Haifa, Israel

Sunday, 5 March, 2017

08:00 Registration

08:30-10:00 Plenary Session 10: Combination and Cardiovascular Disease
Chairs: **Flávio D. Fuchs**, Brazil; **Andrzej Januszewicz**, Poland

Hall A

- 08:30 Cardiovascular Outcome Trials in Diabetes: Cardiologist's Point of View
Francesco Cosentino, Cardiology Unit, Dept. of Medicine, Karolinska University Hospital, Solna, Sweden
- 08:55 Combination Therapy in the Management of Stable Coronary Artery Disease in the PCI Era
Giuseppe Ambrosio, Dept. of Cardiology, University of Perugia School of Medicine, Perugia, Italy
- 09:20 What is the Optimal Two-Drug and Three-Drug Fixed Combination?
Andrzej Januszewicz, Dept. of Hypertension, Institute of Cardiology, Warsaw, Poland
- 09:35 Comparison of the Effects of Zofenopril or Ramipril Plus Acetylsalicylic Acid in Post-Myocardial Infarction Patients with Left Ventricular Systolic Dysfunction
Salvatore Novo, Dept. of Internal Medicine and Cardiovascular Disease, University of Palermo, Italy
-

10:00-10:30 Coffee Break, Exhibition Visit and Posters Viewing

10:30-12:30 Closing Plenary Session 11: Combination Therapy

Chairs: **Talma Rosenthal**, Israel; **Reuven Zimlichman**, Israel

Hall A

- 10:30 Amiloride, an Obligatory Companion of Chlorthalidone and other Diuretics
Flávio D. Fuchs, Hospital de Clinicas de Porto Alegre, Brazil
- 10:55 Combination Therapy and Kidney Outcome-What should be the Target?
Bojan Jelakovic, University of Zagreb School of Medicine, University Hospital Center Zagreb, Croatia
- 11:20 TIPS and TRICKS to Motivate Patient to take Combination Therapy
Atul Pathak, Cardiologie / Pharmacologie, Clinique Pasteur, INSERM 1048, Centre de Recherche Clinique Cardiovasculaire Pasteur / CHU, France
- 11:45 Combination Therapy in the Hypertensive Patient with Coronary Artery Disease
Paolo Palatini, Dept. of Medicine, Vascular Medicine, University of Padova, Italy
- 12:10 Conclusion

Poster Presentations

1. Risk of Obstructive Sleep Apnea among Patients with Type 2 Diabetes in Saudi Arabia
Metab Algeffari, Family Medicine Department, Qassim University College of Medicine, Saudi Arabia
2. A Fixed Combination of Lisinopril and Amlodipine in the Treatment of Overweight Patients with Arterial Hypertension and Coronary Heart Disease
Albert Galyavich, Dept. of Cardiology, Kazan State Medical University, Russia
3. Fixed Antihypertensive Combination Amlodipine/Indapamide Reduces Amlodipine-Induced Lower Leg Edema
Iana Simova, Dept. of Cardiology, National Multiprofile Transport Hospital Tsar Boris III, Bulgaria
4. Assessment of Quality of Life And Co Morbidity Resolution after Laparoscopic Sleeve Gastrectomy in Obese North Indian Population-A Prospective Single Institution Study
Amal Pushp Singh, General Surgery, Asian Institute of Medical Sciences, India
5. Combination of Lisinopril Hydrochlorothiazide and Amlodipine of Ukrainian Production Effectively Lowers Blood Pressure and Central Blood Pressure
Olena Torbas, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D. Strazhesko, Ukraine
6. The Influence of Metabolic Factors on Central Blood Pressure Lowering Effect of Lisinopril or Bisoprolol Plus Hydrochlorothiazide and Amlodipine
Olena Torbas, Symptomatic Hypertension, FI NSC Institute of Cardiology n.a. M.D. Strazhesko, Ukraine

7. Celecoxib FDCs for the treatment of Arthritis
Vuong Trieu, R&D, Marina Biotech, USA
8. Add-on Empagliflozin Therapy (Alone or in Fixed Combination) Can Reduce the Risk of Cardiovascular Disease in People with TYPE 2 Diabetes
Katarina Vukelic, Dept of Diabetes, Health Centre Grosuplje, Slovenia
9. The Association of Pediatric Obesity with Dyslipidemia, Type 2 Diabetes and Hypertension
Michael Yafi, Dept. of Pediatrics, the University of Texas at Houston Health Science Center, USA
10. Effects of the Fixed Combination of Losartan and Hydrochlorothiazide on Blood Pressure in Hypertensive Patients with Diabetic Nephropathy
Gen Yasuda, Dept. of Nephrology, Yokohama City University, Japan